Reporting the accuracy of diagnostic tests: The STARD initiative 10 years on

Clinical Chemistry

Volumn 59, Issue 6, 2013, Pages 917-919

  Ochodo, Eleanor A ^a   Bossuyt, Patrick M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CHECKLIST; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HEALTH CARE ORGANIZATION; HUMAN; NOTE; PRACTICE GUIDELINE; PUBLICATION;

DIAGNOSTIC TESTS, ROUTINE; GUIDELINES AS TOPIC; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 84878458725     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.206516     Document Type: Note

References (12)

1. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004;140:189-202. (Pubitemid 38155650)
2. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003;49:1-6. (Pubitemid 36078546)
3. Bossuyt PM. STARD statement: still room for improvement in the reporting of diagnostic accuracy studies. Radiology 2008;248:713-4.
4. Selman TJ, Morris RK, Zamora J, Khan KS. The quality of reporting of primary test accuracy studies in obstetrics and gynaecology: application of the STARD criteria. BMC Womens Health 2011;11:8.
5. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal 'Instructions to Authors'. Trials 2008;9:20.
6. Smidt N, Overbeke J, de VH, Bossuyt P. Endorsement of the STARD statement by biomedical journals: survey of instructions for authors. Clin Chem 2007;53:1983-5. (Pubitemid 350036050)
7. CONSORT: Transparent Reporting of Trials. Extensions of the CONSORT Statement. http://www.consort-statement.org/extensions/ (Accessed April 2012).
8. Saah AJ, Hoover DR. "Sensitivity" and "specificity" reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med 1997;126:91-4. (Pubitemid 27021232)
9. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). J Natl Cancer Inst 2005;97:1180-4. (Pubitemid 41258223)
10. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med 2008;5:e20.
11. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7.
12. Hooft L, Bossuyt PM. Prospective registration of marker evaluation studies: time to act. Clin Chem 2011;57:1684-6.